OAKLAND, Calif.--(BUSINESS WIRE)--OrthoTrophix, Inc. (www.orthotrophix.com), a privately-held biopharmaceutical company, announced today that the company and its collaborators are presenting Phase 2 clinical study data at the European Congress of Rheumatology in Madrid, Spain (June 12 – 15). The presentation, entitled “Improved Knee Physical Function Correlates Significantly with TF Cartilage Thickness Increase after IA TPX-100” is abstract THU0441.
Knee function, measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 6 and 12 months, was markedly improved in TPX-100-treated knees compared to placebo-exposed knees. Twelve months after TPX-100, knee function improvement was sustained and correlated significantly with tibiofemoral cartilage thickness stabilization or increase (p<0.01).
“Concordances between meaningful patient benefits and structural benefits are critical for development of a disease-modifying drug for osteoarthritis (DMOAD),” commented OrthoTrophix’ Chief Medical Officer, Dr. Dawn McGuire. “These results complement recent findings that TPX-100 treatment reduces pathological bone shape change in the patella at 12 months, which correlates with a clinically meaningful decrease in the frequency of knee pain. We believe TPX-100 has the potential to alter the disease course of knee OA both clinically and structurally.”
About OrthoTrophix, Inc.
OrthoTrophix, Inc., based in Oakland, California, is a privately held biopharmaceutical company focused on the development and commercialization of revolutionary therapeutics for the treatment of diseases and conditions involving the hard tissues. Founded by three co-founders in 2011, the primary focus of OrthoTrophix has been regeneration and repair of cartilage in the knee and other joints with its novel proprietary compounds which promote formation of new cartilage and bone tissues and thereby repair the respective defects.
This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. OrthoTrophix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect OrthoTrophix’ business.
